The potential role of lonidamine (LND) in the treatment of malignant glioma

✍ Scribed by Carmine M. Carapella; Marco G. Paggi; Fabio Cattani; Giovanni B. Ciottoli; Aristide Floridi; Bruno Iandolo; Laura Raus; Antonio Riccio; Antonio Caputo

• Book ID: 104642781
• Publisher: Springer US
• Year: 1989
• Tongue: English
• Weight: 397 KB
• Volume: 7
• Category: Article
• ISSN: 0167-594X
• DOI: 10.1007/bf00149384

✦ Synopsis

Up-to-date unsatisfactory results obtained in multimodality treatments of malignant glioma have prompted the research of new therapeutic modalities with 'unconventional' modes of action. Lonidamine (LND) is a drug which reduces aerobic glycolytic activity in both human and experimental tumors. This effect mainly depends on the inhibition of mitochondrially-bound hexokinase (HK) which is present in large amounts in malignant cells. A Phase II study was conducted on patients with recurrent glioma; 12 patients were admitted to the study. Clinical side effects were moderate, necessitating a reduction of the dosage in only 1 case. The objective results were evaluated according to the indications of Levin. 2 responders and 3 cases of stable disease were observed out of 10 evaluable patients. The potential value of this new drug is discussed.

Address for offprints.'M. Carapella, '